Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Tsuji D, Nakagaki S, Yonezawa I, Suzuki K, Yokokawa T, Kawasaki Y, Yamaguchi T, Kawaguchi T, Hatori M, Matsumoto T, Sakata Y, Yamamoto K, Nishimura T, Kogure Y, Hayashi T, Osawa M, Itoh K, Watanabe M. Tsuji D, et al. Among authors: kogure y. Invest New Drugs. 2024 Feb;42(1):44-52. doi: 10.1007/s10637-023-01414-y. Epub 2023 Dec 6. Invest New Drugs. 2024. PMID: 38055127 Clinical Trial.
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.
Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Tsuji D, et al. Among authors: kogure y. Pharmacogenomics J. 2017 Oct;17(5):435-440. doi: 10.1038/tpj.2016.38. Epub 2016 May 31. Pharmacogenomics J. 2017. PMID: 27241063
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N. Suzuki K, et al. Among authors: kogure y. Ann Oncol. 2016 Aug;27(8):1601-6. doi: 10.1093/annonc/mdw220. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358385 Free article. Clinical Trial.
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Kizaki M, et al. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14. Int J Hematol. 2019. PMID: 30762219 Clinical Trial.
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K. Matsui R, et al. Among authors: kogure y. BMC Pharmacol Toxicol. 2020 Oct 6;21(1):72. doi: 10.1186/s40360-020-00445-y. BMC Pharmacol Toxicol. 2020. PMID: 33023657 Free PMC article.
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, Osada-Tsuchiya M, Otake A, Nakao M, Yano T, Arakawa Y, Matsuo K, Ohashi Y, Sakata Y, Kogure Y, Tamaki S, Wada A, Taki Y, Sasahira N, Ishii H, Yamaguchi M, Itoh K. Hatori M, et al. Among authors: kogure y. Cancer. 2024 Apr 29. doi: 10.1002/cncr.35343. Online ahead of print. Cancer. 2024. PMID: 38682652
A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, Iwamoto Y, Sasaki H, Takeda K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y; West Japan Oncology Group. Hirai F, et al. Among authors: kogure y. Ann Oncol. 2015 Feb;26(2):363-8. doi: 10.1093/annonc/mdu541. Epub 2014 Nov 17. Ann Oncol. 2015. PMID: 25403584 Free article. Clinical Trial.
A case of community-acquired Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus (MRSA) necrotizing pneumonia successfully treated with two anti-MRSA drugs.
Shiiba R, Sano M, Kogure Y, Murao H, Takigawa Y, Torii A, Yamada A, Shinohara Y, Niwa H, Kitagawa C, Oki M. Shiiba R, et al. Among authors: kogure y. Respir Med Case Rep. 2024 Apr 18;49:102023. doi: 10.1016/j.rmcr.2024.102023. eCollection 2024. Respir Med Case Rep. 2024. PMID: 38681212 Free PMC article.
Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK/T-cell lymphoma.
Ito Y, Marouf A, Kogure Y, Koya J, Liévin R, Bruneau J, Tabata M, Saito Y, Shingaki S, Yuasa M, Yamaguchi K, Murakami K, Weil R, Vavasseur M, Andrieu GP, Latiri M, Veleanu L, Dussiot M, André I, Joshi A, Lagresle-Peyrou C, Magerus A, Chaubard S, Lavergne D, Bachy E, Brunet E, Fataccioli V, Brouzes C, Laurent C, De Leval L, Traverse-Glehen A, Bossard C, Parrens MC, Meignin V, Philippe L, Rossignol J, Suarez F, Michot JM, Tournilhac O, Damaj G, Lemonnier F, Bôle-Feysot C, Nitschké P, Tesson B, Laurent C, Molina T, Asnafi V, Watatani Y, Chiba K, Okada A, Shiraishi Y, Tsukita S, Izutsu K, Miyoshi H, Ohshima K, Sakata S, Dobashi A, Takeuchi K, Sanada M, Gaulard P, Jaccard A, Ogawa S, Hermine O, Kataoka K, Couronné L. Ito Y, et al. Among authors: kogure y. Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-24-0132. Online ahead of print. Cancer Res. 2024. PMID: 38657099
204 results